HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about.
One you should research right away, BioRestorative Therapies, Inc. (BRTX) a life sciences company focused on stem cell-based therapies, is developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue. The company traded above $3 dollars last year before hitting lows with the rest of the biotech industry. The company has started to rally in lockstep with the industry's ETF: IBB, and could be on the verge of a breakout that may send BRTX above their 2018 highs. Get a jumpstart on the crowd by researching BRTX today.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Celldex Therapeutics, Inc. (CLDX), Geron Corporation (GERN), 22nd Century Group, Inc. (NYSE American: XXII) and Zynerba Pharmaceuticals, Inc. (ZYNE).
According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.
One of the more novel approaches to fighting this obesity epidemic is being developed by, BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.353M Share Price: $0.70) a life sciences company focused on stem cell-based therapies, developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span the US, Australia, and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
Celldex Therapeutics, Inc. (CLDX) (Market Cap: $67.589M Share Price: $0.39) presented data from the Company's MerTK antibody program in a poster session recently at the Society for Immunotherapy of Cancer's (SITC) 33rdAnnual Meeting. MerTK is emerging as a promising target for cancer immunotherapy.
Geron Corporation (GERN) (Market Cap: $242.252M Share Price: $1.30) announced positive results from its dose-finding pharmacokinetic ("PK") study - INS015-18-124 - evaluating proprietary formulation of epinephrine nasal spray for treating anaphylaxis, an acute, life-threatening allergic reaction. Data from the study showed that the candidate has a similar PK profile with Mylan's MYL EpiPen as well as Par Pharmaceuticals' Adrenalin (epinephrine injection).
22nd Century Group, Inc. (XXII) (Market Cap: $311.00M Share Price: $2.50) submitted a Modified Risk Tobacco Product (MRTP) application with the U.S. Food and Drug Administration (FDA) for the Company's Very Low Nicotine Content (VLNC) cigarettes. The 22nd Century's proposed VLNTM cigarettes, the subject of the MRTP application, are made with the Company's proprietary VLNTM tobacco and, as a result, contain very low levels of nicotine.
Zynerba Pharmaceuticals, Inc. (ZYNE) (Market Cap: $92.717M Share Price: $5.26) released 12-month clinical data that describes the lifelong impact of ZYN002 on developmental and responsive symptoms of Fragile X syndrome. In a poster for the presentation in the 57th annual meeting, Professor Steven Siegel gives the presentation of the 12-month data of the second phase of the clinical trial of […] The post-Zynerba Gives Clinical Update, Lifelong Impact Of ZYN002 appeared first on Market Exclusive.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
SOURCE: Regal Consulting, LLC
View source version on accesswire.com: